Ironwood Pharmaceuticals IRWD Debt-to-equity
Discontinued — last reported Q1 '23
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Ironwood Pharmaceuticals’s reported figures.
Based on the most recent quarter.
The official record: Ironwood Pharmaceuticals’s 10-Q, filed May 9, 2024, on SEC EDGAR. View the filing →
Ask your AI about Ironwood Pharmaceuticals's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ironwood Pharmaceuticals's debt-to-equity?
- Ironwood Pharmaceuticals (IRWD) reported debt-to-equity of 0× in Q1 2023.
- How has Ironwood Pharmaceuticals's debt-to-equity changed year-over-year?
- Ironwood Pharmaceuticals's debt-to-equity decreased by 94.7% year-over-year, from 0.5× to 0×.
- What is the long-term trend for Ironwood Pharmaceuticals's debt-to-equity?
- Over 2 years (2020 to 2022), Ironwood Pharmaceuticals's debt-to-equity has grown at a -71.6% compound annual growth rate (CAGR), from 0.4× to 0×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.